Vanguard Group Inc. Sells 33,944 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Vanguard Group Inc. lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 0.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,286,346 shares of the biopharmaceutical company's stock after selling 33,944 shares during the quarter. Vanguard Group Inc. owned about 8.45% of Regeneron Pharmaceuticals worth $6,614,943,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Amundi lifted its position in shares of Regeneron Pharmaceuticals by 45.8% during the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after buying an additional 487,489 shares during the last quarter. Proficio Capital Partners LLC boosted its stake in shares of Regeneron Pharmaceuticals by 92,865.3% in the 4th quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company's stock valued at $156,284,000 after purchasing an additional 219,162 shares in the last quarter. Worldquant Millennium Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $127,489,000. Thrivent Financial for Lutherans increased its position in Regeneron Pharmaceuticals by 1,272.7% during the 4th quarter. Thrivent Financial for Lutherans now owns 125,194 shares of the biopharmaceutical company's stock worth $89,179,000 after purchasing an additional 116,074 shares in the last quarter. Finally, KBC Group NV lifted its stake in Regeneron Pharmaceuticals by 296.7% in the 4th quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company's stock valued at $97,338,000 after purchasing an additional 102,198 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on REGN shares. Citigroup lowered their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Bank of America reiterated an "underperform" rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. TD Cowen decreased their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a report on Tuesday, February 4th. Leerink Partners upgraded Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and upped their target price for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. Finally, Bernstein Bank lowered their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN traded down $2.05 during mid-day trading on Friday, hitting $633.78. The stock had a trading volume of 69,089 shares, compared to its average volume of 639,950. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm has a market cap of $69.29 billion, a P/E ratio of 16.55, a PEG ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a 52 week low of $629.02 and a 52 week high of $1,211.20. The business has a fifty day moving average price of $684.76 and a 200-day moving average price of $803.87.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. During the same quarter in the previous year, the firm posted $11.86 EPS. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.56%. Regeneron Pharmaceuticals's dividend payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.